This and our recent reports highlight how distinct mechanisms of miR-126 dysregulation driven by specific leukemogenic mutations (i.e., CBFB-MYH11, BCR-ABL, FLT3-ITD) play a relevant role in leukemia pathobiology30,31. This evidence concerns the gene ABL1 and leukemia.